Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities

• Published in: Cell stem cell Vol. 22; no. 6; pp. 824 - 833
• Main Authors: Galipeau, Jacques, Sensébé, Luc
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2018
• Subjects: Animals; biomarkers; clinical trials; Crohn’s disease; efferocytosis; FDA; graft versus host disease; Graft vs Host Disease - therapy; Humans; immune compatibility; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - metabolism; mesenchymal stromal cells; thawing; thawing; FDA; immune compatibility; biomarkers; mesenchymal stromal cells; efferocytosis; clinical trials; graft versus host disease; Crohn’s disease
• ISSN: 1934-5909; 1875-9777
• DOI: 10.1016/j.stem.2018.05.004

Mesenchymal stromal cells (MSCs) have been the subject of clinical trials for more than a generation, and the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models. In this Perspective, important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analyses of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs. In this Perspective, Galipeau and Sensébé highlight important biological and pharmacological disparities in pre-clinical research and human translational studies. The authors also analyze clinical trial failures and recent successes to discuss a rational pathway toward MSC regulatory approval and deployment for disorders with unmet medical needs.